๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Current therapy for hepatitis C: pegylated interferon and ribavirin

โœ Scribed by McHutchison, John G; Fried, Michael W

Book ID
123105554
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
108 KB
Volume
7
Category
Article
ISSN
1089-3261

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pegylated interferon and ribavirin thera
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection
โœ F. Legrand-Abravanel; F. Nicot; A. Boulestin; K. Sandres-Saunรฉ; J.P. Vinel; L. A ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB

## Abstract Hepatitis C Virus (HCV) is classified into six genotypes. Genotype 4 is now spreading in Europe, especially among drug users, who are often infected with both HCV and the human immunodeficiency virus (HIV). Previous studies have shown that HCVโ€4 responds poorly to interferon. Pegylated

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
โœ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 240 KB ๐Ÿ‘ 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a